Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Dupilumab is prescribed for treating moderate-to-severe atopic dermatitis in adult patients who do not respond to topical treatments or cannot tolerate standard therapies. It acts as an ...

The following is a summary of “Longitudinal integrated proteomic and metabolomic skin changes in atopic dermatitis patients ...

In some cases, they can radically improve symptoms. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Members of an international team of experts in atopic dermatitis (AD) have recommended oral JAK inhibitors for patients ...

Researchers compiled findings from seven studies demonstrating the real-world utility of tralokinumab for atopic dermatitis ... biologic treatments including dupilumab, abrocitinib and ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting ... across multiple indications, including atopic dermatitis (AD), in which it is considered the gold standard.